Results 61 to 70 of about 55,752 (265)

The effectiveness of contrast bath to reduce joint pain in the elderly

Medisains, 2020
Background: The aging process results in changes in the musculoskeletal system causing a decrease in function of joints, loss of elasticity and limited mobility.
Esri Rusminingsih, Nur Wulan Agustina, Dyah Ayu Nawang Wulan   +2 more
doaj   +1 more source

Serum Proteomic Signatures of Rheumatoid Arthritis Risk and Response: Analysis of a Rheumatoid Arthritis Interception Trial

Arthritis &Rheumatology, EarlyView.
Objective Our study objective was to identify serum protein signatures associated with progression to rheumatoid arthritis (RA) and response to abatacept in at‐risk individuals. Methods A total of 440 serum samples from 118 APIPPRA (Arthritis Prevention In the Preclinical Phase of RA with Abatacept) study participants were selected from baseline to RA ...
Marianna Jasenecova, Carl Coyle, Alina Mihalovits, Sarah Ryan, Elizabeth Pook, Esperanza Perucha, Gabrielle Harker, Melody Chin, Sam Norton, Andrew P. Cope   +9 more
wiley   +1 more source

Safety, tolerability and pharmacokinetics of DNDI‐6148, a novel agent for leishmaniasis: A randomized, controlled, single ascending dose study in healthy participants

British Journal of Clinical Pharmacology, EarlyView.
Aim The benzoxaborole derivative DNDI‐6148 is an antiparasitic agent with activity against multiple Leishmania protozoan species, including L. infantum and L. donovani, which cause visceral leishmaniasis. We investigated the safety, tolerability and pharmacokinetics of single oral doses of DNDI‐6148 in a randomized, parallel‐group, placebo‐controlled ...
Jean‐Yves Gillon, Sophie Delhomme, Delphine Launay, Séverine Blesson, Stéphanie Braillard, Pegah Maghdooni, Frauke Assmus, Richard Hoglund, Joel Tarning, Sabrina Loyau, Byron Arana, Mathilde Latreille‐Barbier, Yves Donazzolo   +12 more
wiley   +1 more source

REVISITING THE DIAGNOSIS OF PSORIATIC ARTHRITIS IN PATIENTS WITH PSORIASIS

Alʹmanah Kliničeskoj Mediciny, 2016
Aim: To study clinical and x-ray characteristics of psoriatic arthritis in patients with psoriasis during hospital treatment in the Dermatovenereology and Dermato-Oncology Department of the Moscow Regional Research and Clinical Institute (MONIKI ...
E. S. Yakubovskaya
doaj   +1 more source

Risk of cardiac, neuropsychiatric and musculoskeletal adverse events with levothyroxine: Systematic review

British Journal of Clinical Pharmacology, EarlyView.
Abstract Levothyroxine (LT4) is the standard treatment for hypothyroidism and the most widely prescribed medication worldwide. Although generally safe, regulatory reports list potential cardiac, neuropsychiatric and musculoskeletal adverse events (AEs). Clarifying their clinical relevance is essential.
Bala Swetha Baskaran, Mohammad Ali Omrani, Flory T. Muanda   +2 more
wiley   +1 more source

Clinical Safety of Extended Interval Dosing of Nivolumab in Patients with Melanoma

Clinical Pharmacology &Therapeutics, EarlyView.
Extended interval dosing regimens of immune checkpoint inhibitors have been implemented widely. However, their approval was mainly based on pharmacokinetic modeling and simulations. Consequently, comparative safety data of extended interval dosing regimens in a real‐world setting are limited.
Ruben Malmberg, Maaike M. Hofman, Fatima Ashad, Alaa Daloul, Stefani Oosterveld, Edwin A. Basak, Esther Oomen‐de Hoop, Astrid A. M. van der Veldt, Arjen Joosse, Roelof W. F. van Leeuwen, Ron H. J. Mathijssen   +10 more
wiley   +1 more source

Arthritis Post-Immunotherapy for Endometrial Cancer: a case report and review of literature on the acute onset of inflammatory arthritis following PD-I inhibitor therapy in a patient with recurrent endometrial cancer

Marshall Journal of Medicine, 2021
Since gaining FDA approval in 2014, pembrolizumab, a PD-1 immune checkpoint inhibitor, has been utilized in the management of cancers that progress following first-line therapy.While the pathological response to pembrolizumab is favorable, immune related
Sydney Graham, Emily Sloane, Nadim Bou Zgheib   +2 more
doaj   +1 more source

Association of Pregabalin vs. Duloxetine with Cardiovascular Events: A Retrospective Cohort Study Among US Veterans With Chronic Musculoskeletal Pain

Clinical Pharmacology &Therapeutics, EarlyView.
Pregabalin and duloxetine are widely prescribed non‐opioid medications for chronic musculoskeletal pain. Pregabalin may increase the risk of heart failure, and duloxetine increases heart rate and blood pressure; however, little is known about their comparative cardiovascular safety.
Sachalee Campbell, Puran Nepal, Laura Daniel, Otis Wilson, Alyson L. Dickson, Jennifer Maizel, Katherine T. Murray, William D. Dupont, Adriana Hung, Wayne A. Ray, C. Michael Stein, Cecilia P. Chung   +11 more
wiley   +1 more source

Real‐world progression‐free survival and overall survival in patients with HR+/HER2− advanced breast cancer treated in first‐line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study

International Journal of Cancer, EarlyView.
What's New? The CDK4/6 inhibitor ribociclib in combination with an endocrine‐based therapy has demonstrated significant progression‐free and overall survival benefits in patients with advanced/metastatic HR+/HER2‐ breast cancer in the pivotal MONALEESA trials.
Peter A. Fasching, Cosima Brucker, Thomas Decker, Anne Engel, Thomas Göhler, Christian Jackisch, Jan Janssen, Andreas Köhler, Kerstin Lüdtke‐Heckenkamp, Diana Lüftner, Frederik Marmé, Marion van Mackelenbergh, Beate Rautenberg, Marcus Schmidt, Rudolf Weide, Pauline Wimberger, Elena Kisseleff, Christina Pfister, Claudia Quiering, Christian Roos, Achim Wöckel   +20 more
wiley   +1 more source

Impact of Unilateral Chewing Habit on Temporomandibular Joint Disorders: A Comparative Study

Journal of Indian Academy of Oral Medicine and Radiology
Background: Temporomandibular joint disorders (TMD) are known to have a significant impact on muscle function, joint health, and quality of life. Unilateral chewing habit has come up as a possible risk factor.
Tabarak S. Abbas, Ghaith M. Al-hamdani, Karar A. Mahdi   +2 more
doaj   +1 more source